Clinical significance of serum angiocidin levels in hepatocellular carcinoma

Cancer Letters

Volumn 251, Issue 1, 2007, Pages 28-35

  Sabherwal, Yamini ^a   Rothman, Vicki L ^a   Poon, Ronnie T P ^b   Tuszynski, George P ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiocidin; Angiogenesis; Hepatocellular carcinoma; Metastasis; Tumor markers

Indexed keywords

ANGIOCIDIN; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; PREDICTION; PRIORITY JOURNAL; SERUM;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REFERENCE STANDARDS;

EID: 34247154377     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.10.023     Document Type: Article

References (18)

1. Varela M., Sala M., Llovet J.M., and Bruix J. Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer Treat. Rev. 29 (2003) 99-104
2. Zhou L., Liu J., and Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 12 (2006) 1175-1181
3. Zhou J., Rothman V.L., Sargiannidou I., Dimitrov S., Qiu C., Smith E., Sheffield J., Sharma M., and Tuszynski G.P. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J. Cell. Biochem. 92 (2004) 125-146
4. Sabherwal Y., Rothman V.L., Dimitrov S., L'Heureux D., Marcinkiewicz C., Sharma M., and Tuszynski G.P. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell Res. 312 (2006) 2443-2453
5. Tuszynski G.P., Rothman V.L., Papale M., Hamilton B.K., and Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J. Cell Biol. 120 (1993) 513-521
6. Poon R.T., Chung K.K., Cheung S.T., Lau C.P., Tong S.W., Leung K.L., Yu W.C., Tuszynski G.P., and Fan S.T. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 10 (2004) 4150-4157
7. Tahara T., Usuki K., Sato H., Ohashi H., Morita H., Tsumura H., Matsumoto A., Miyazaki H., Urabe A., and Kato T. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br. J. Haematol. 93 (1996) 783-788
8. Tuszynski G.P., and Nicosia R.F. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab. Invest. 70 (1994) 228-233
9. Arnoletti J.P., Albo D., Jhala N., Granick M.S., Solomon M.P., Atkinson B., Rothman V.L., and Tuszynski G.P. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am. J. Surg. 168 (1994) 433-436
10. Wakiyama T., Shinohara T., Shirakusa T., John A.S., and Tuszynski G.P. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol. Histopathol. 16 (2001) 345-351
11. Young P., Deveraux Q., Beal R.E., Pickart C.M., and Rechsteiner M. Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. J. Biol. Chem. 273 (1998) 5461-5467
12. Nilsson L.A., Lange S., and Lonnroth I. Induction of anti-secretory factor in mice by the nonintestinal parasite Schistosoma mansoni. J. Parasitol. 78 (1992) 1055-1058
13. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
14. Sabherwal Y., Rothman V., Albo D., and Tuszynski G. Angiocidin, an endogenous inhibitor of angiogenesis, is increased in the sera of cancer patients. Proc. Am. Assoc. Canc. Res. 45 (2004) 1143
15. Sabherwal Y., Rothman V.L., and Tuszynski G.P. Sensitive capture ELISA for measuring angiocidin in human serum: serum angiocidin levels in healthy volunteers and in prostate cancer patients. Proc. Am. Assoc. Canc. Res. 46 (2005) 743
16. Sabherwal Y., Rothman V.L., Poon R.T., and Tuszynski G.P. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Proc. Am. Assoc. Canc. Res. 46 (2005) 1319
17. Okusaka T., Okada S., Ueno H., Ikeda M., Shimada K., Yamamoto J., Kosuge T., Yamasaki S., Fukushima N., and Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 95 (2002) 1931-1937
18. Tanaka K., Kondoh N., Shuda M., Matsubara O., Imazeki N., Ryo A., Wakatsuki T., Hada A., Goseki N., Igari T., Hatsuse K., Aihara T., Horiuchi S., Yamamoto N., and Yamamoto M. Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. Biochim. Biophys. Acta 1536 (2001) 1-12